Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients

Dendritic cells (DCs) are highly effective antigen (Ag)-presenting cells (APCs) that are required for the initiation of the immune response. DCs derived from cancer patients have been shown to be defective in several phenotypic and functional properties. However, little is known about the capacity of monocytes derived From cancer patients to differentiate into DCs. Herein, we examined the differentiation of monocyte-derived DCs, in cancer patients. Flow cytometric analysis revealed that monocytes derived From cancer patients cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) plus interleukin-1 (IL-4) exhibited lower levels of CD11c, CD40, CD86, and HLA-DR expression as compared with those of monocyte-derived DCs from healthy volunters. Furthermore, the capacities of DCs derived fi om cancer patients' monocytes to stimulate allogeneic T cell responses and to migrate in response to regulated-on-activation normal T cells expressed and secreted (RANTES) were impaired in comparison with those of monocyte-derived DCs from healthy volunteers. However, the two cell types had similar pinocytotic capacities For fluorescein isothiocyanate labeled-dextran (FITC-DX) and lucifer yellow: (LY). These results suggest that monocytes from cancer patients may be defective in the capacity to develop into DCs. (C) 2000 Editions scientifiques et medicales Elsevier SAS.